Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,047 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, Texter M, Pressler ML, Black D, Chaitman BR, Olsson AG. Schwartz GG, et al. Among authors: ganz p. Am J Cardiol. 1998 Mar 1;81(5):578-81. doi: 10.1016/s0002-9149(97)00963-6. Am J Cardiol. 1998. PMID: 9514453
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T; MIRACL Study Investigators. Waters DD, et al. Among authors: ganz p. Circulation. 2002 Sep 24;106(13):1690-5. doi: 10.1161/01.cir.0000031568.40630.1c. Circulation. 2002. PMID: 12270864 Clinical Trial.
Effect of ACAT inhibition on the progression of coronary atherosclerosis.
Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfield JE, Wisniewski LM, Hanyok JJ, Kassalow LM; ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators. Nissen SE, et al. Among authors: ganz p. N Engl J Med. 2006 Mar 23;354(12):1253-63. doi: 10.1056/NEJMoa054699. N Engl J Med. 2006. PMID: 16554527 Free article. Clinical Trial.
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Kinlay S, et al. Among authors: ganz p. Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):142-7. doi: 10.1161/ATVBAHA.107.151787. Epub 2007 Nov 8. Arterioscler Thromb Vasc Biol. 2008. PMID: 17991875 Clinical Trial.
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S; MIRACL Study Investigators. Fraley AE, et al. Among authors: ganz p. J Am Coll Cardiol. 2009 Jun 9;53(23):2186-96. doi: 10.1016/j.jacc.2009.02.041. J Am Coll Cardiol. 2009. PMID: 19497447 Free article. Clinical Trial.
1,047 results